Just one month into his CEO tenure at ADC Therapeutics, Ameet Mallik is bringing in new people to assemble his top team.
David Gilman, a seasoned biopharma consultant who held a brief stint scouting deals for Novartis’ oncology group, is joining the Swiss biotech as chief business and strategy officer.
A veteran of Novartis himself, Mallik jumped to ADC last month after his first CEO experience at Rafael Holdings imploded, replacing Chris Martin, the long-time chief who’d been involved with the company since its formation in 2011 and oversaw a slate of financings, deals, an IPO and an FDA approval.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 143,900+ biopharma pros reading Endpoints daily — and it’s free.
SIGN UP
LOG IN
